UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

Moral Distress, Workplace Health, and Intrinsic Harm

Bioethics, 2016-05, Vol.30 (4), p.244-250

Weber, Elijah

2016

Link zum Volltext

Verfügbarkeit prüfen

Development of a microphysiological model of human kidney proximal tubule function

Kidney international, 2016-09, Vol.90 (3), p.627-637

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment

Journal of clinical pharmacology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue Chip

Scientific reports, 2018-10, Vol.8 (1), p.14882-14, Article 14882

2018

Link zum Volltext

Verfügbarkeit prüfen

A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro

Journal of the American Society of Nephrology, 2016-04, Vol.27 (4), p.1015-1028

2016

Link zum Volltext

Verfügbarkeit prüfen

Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity

JCI insight, 2018-12, Vol.3 (24)

2018

Link zum Volltext

Verfügbarkeit prüfen

Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity

JCI insight, 2017-11, Vol.2 (22)

2017

Link zum Volltext

Verfügbarkeit prüfen

A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation

Journal of the American Society of Nephrology, 2018-12, Vol.29 (12), p.2820-2833

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Clinical pharmacology in drug development, 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

Concise review: Current and emerging biomarkers of nephrotoxicity

Current opinion in toxicology, 2017-06, Vol.4, p.16-21

2017

Link zum Volltext

Verfügbarkeit prüfen

Microphysiological Systems to Assess Nonclinical Toxicity

Current Protocols in Toxicology, 2017-08, Vol.73 (1), p.14.18.1-14.18.28

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0134423

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

Clinical pharmacokinetics, 2024-02, Vol.63 (2), p.241-253

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Disposition, and Biotransformation of [ 14C] Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

Clinical pharmacokinetics, 2024-02, Vol.63 (2), p.241-253

2024

Link zum Volltext

Verfügbarkeit prüfen

Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Journal of clinical pharmacology, 2023-05, Vol.63 (5), p.560-568

2023

Link zum Volltext

Verfügbarkeit prüfen

Context-Dependence in Searle’s Impossibility Argument: A Reply to Butchard and D’Amico

Philosophy of the social sciences, 2012-09, Vol.42 (3), p.433-444

Weber, Elijah

2012

Link zum Volltext

Verfügbarkeit prüfen

Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor

Journal of hepatology, 2020-08, Vol.73, p.S445

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI094 - The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)

Journal of hepatology, 2020-08, Vol.73, p.S445-S445

2020

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment

Journal of hepatology, 2020-08, Vol.73, p.S444-S445

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI093 - Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor

Journal of hepatology, 2020-08, Vol.73, p.S445-S445

2020

Link zum Volltext

Verfügbarkeit prüfen

The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)

Journal of hepatology, 2020-08, Vol.73, p.S445

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI092 - The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment

Journal of hepatology, 2020-08, Vol.73, p.S444-S445

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist

Clinical pharmacokinetics, 2023-04, Vol.62 (4), p.609-621

2023

Link zum Volltext

Verfügbarkeit prüfen

Liver and Kidney on Chips: Microphysiological Models to Understand Transporter Function

Clinical pharmacology and therapeutics, 2016-11, Vol.100 (5), p.464-478

2016

Link zum Volltext

Verfügbarkeit prüfen

The V‐ATPase Subunit d: New Roles for Functionally and Structurally Coupling of V1‐Vo

The FASEB journal, 2012-04, Vol.26 (S1)

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(58)

Publikationsform

Sprache

Englisch
(70)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Moral Distress, Workplace Health, and Intrinsic Harm

Development of a microphysiological model of human kidney proximal tubule function

Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment

Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue Chip

A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro

Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity

Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity

A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation

Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Concise review: Current and emerging biomarkers of nephrotoxicity

Microphysiological Systems to Assess Nonclinical Toxicity

Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment

Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

Pharmacokinetics, Disposition, and Biotransformation of [ 14C] Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Context-Dependence in Searle’s Impossibility Argument: A Reply to Butchard and D’Amico

Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor

FRI094 - The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)

The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment

FRI093 - Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor

The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)

FRI092 - The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist

Liver and Kidney on Chips: Microphysiological Models to Understand Transporter Function

The V‐ATPase Subunit d: New Roles for Functionally and Structurally Coupling of V1‐Vo

Suchergebnisse filtern